Next Article in Journal
Development of an Antibody for Detection of Rhamnolipids Characterized as a Major Bacterial Virulence Factor
Previous Article in Journal
Molecular Engineering of Therapeutic Cytokines
Previous Article in Special Issue
Generation of a Monoclonal Antibody Specifically Reacting with Neuron-specific TATA-Box Binding Protein-Associated Factor 1 (N-TAF1)
Article Menu

Export Article

Open AccessReview
Antibodies 2013, 2(3), 452-500;

Developments and Challenges for mAb-Based Therapeutics

Pfizer, Pharmaceutical R&D – BioTherapeutics Pharmaceutical Sciences, 700 Chesterfield Parkway West, Chesterfield, MO 63017, USA
Alliance Protein Laboratories, 6042 Cornerstone Ct West, Suite A1, San Diego, CA 92121, USA
Author to whom correspondence should be addressed.
Received: 23 May 2013 / Revised: 18 July 2013 / Accepted: 2 August 2013 / Published: 16 August 2013
Full-Text   |   PDF [867 KB, uploaded 16 August 2013]   |  


The continuous increase in the number of approved monoclonal antibody (mAb)-based therapy suggests that mAbs, and their derivatives, will continue to be the focus of the biotherapeutics industry for years to come. Although vast improvements in our capability to manufacture, characterize, and stabilize mAbs have been achieved, there are still challenges to be overcome. These include analytical and stabilization approaches associated with the development of high concentration mAb formulations. In addition, several mAb-based modalities are under development, including antibody drug conjugates (ADCs), fusion proteins, and bispecific antibodies (bsAbs), all designed to overcome the limitations encountered with mAb therapy. The current status of their development, with emphasis on manufacturing challenges as well as preliminary clinical results, will be reviewed. View Full-Text
Keywords: monoclonal antibody; fusion-proteins; antibody drug conjugates; fragments; bi-specific monoclonal antibody; fusion-proteins; antibody drug conjugates; fragments; bi-specific

Figure 1

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Goswami, S.; Wang, W.; Arakawa, T.; Ohtake, S. Developments and Challenges for mAb-Based Therapeutics. Antibodies 2013, 2, 452-500.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Antibodies EISSN 2073-4468 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top